TY - JOUR T1 - A DNA damage repair gene-associated signature predicts responses of patients with advanced soft-tissue sarcoma to treatment with trabectedin. JF - Mol Oncol Y1 - 2021 A1 - Moura, David S A1 - Peña-Chilet, Maria A1 - Cordero Varela, Juan Antonio A1 - Alvarez-Alegret, Ramiro A1 - Agra-Pujol, Carolina A1 - Izquierdo, Francisco A1 - Ramos, Rafael A1 - Ortega-Medina, Luis A1 - Martin-Davila, Francisco A1 - Castilla-Ramirez, Carolina A1 - Hernandez-Leon, Carmen Nieves A1 - Romagosa, Cleofe A1 - Vaz Salgado, Maria Angeles A1 - Lavernia, Javier A1 - Bagué, Silvia A1 - Mayodormo-Aranda, Empar A1 - Vicioso, Luis A1 - Hernández Barceló, Jose Emilio A1 - Rubio-Casadevall, Jordi A1 - de Juan, Ana A1 - Fiaño-Valverde, Maria Concepcion A1 - Hindi, Nadia A1 - Lopez-Alvarez, Maria A1 - Lacerenza, Serena A1 - Dopazo, Joaquin A1 - Gutierrez, Antonio A1 - Alvarez, Rosa A1 - Valverde, Claudia A1 - Martinez-Trufero, Javier A1 - Martin-Broto, Javier AB -

Predictive biomarkers of trabectedin represent an unmet need in advanced soft-tissue sarcomas (STS). DNA damage repair (DDR) genes, involved in homologous recombination or nucleotide excision repair, had been previously described as biomarkers of trabectedin resistance or sensitivity, respectively. The majority of these studies only focused on specific factors (ERCC1, ERCC5, and BRCA1) and did not evaluate several other DDR-related genes that could have a relevant role for trabectedin efficacy. In this retrospective translational study, 118 genes involved in DDR were evaluated to determine, by transcriptomics, a predictive gene signature of trabectedin efficacy. A six-gene predictive signature of trabectedin efficacy was built in a series of 139 tumor samples from patients with advanced STS. Patients in the high-risk gene signature group showed a significantly worse progression-free survival compared with patients in the low-risk group (2.1 vs 6.0 months, respectively). Differential gene expression analysis defined new potential predictive biomarkers of trabectedin sensitivity (PARP3 and CCNH) or resistance (DNAJB11 and PARP1). Our study identified a new gene signature that significantly predicts patients with higher probability to respond to treatment with trabectedin. Targeting some genes of this signature emerges as a potential strategy to enhance trabectedin efficacy.

VL - 15 IS - 12 U1 - https://www.ncbi.nlm.nih.gov/pubmed/33983674?dopt=Abstract ER -